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A B S T R A C T
The human epidermal growth factor receptor 2 (HER2) is a well-known negative prognostic factor in breast
cancer and a target of the monoclonal antibody trastuzumab as well as of other anti-HER2 compounds.
Pioneering works on HER2-positive breast cancer in the 90s’ launched a new era in clinical research and on-
cology practice that has reshaped the natural history of this disease. In diagnostic pathology the HER2 status is
routinely assessed by using a combination of immunohistochemistry (IHC, to evaluate HER2 protein expression
levels) and in situ hybridization (ISH, to assess HER2 gene status). For this purpose, international re-
commendations have been developed by a consensus of experts in the field, which have changed over the years
according to new experimental and clinical data. In this review article we will document the changes that have
contributed to a better evaluation of the HER2 status in clinical practice, furthermore we will discuss HER2
heterogeneity defined by IHC and ISH as well as by transcriptomic analysis and we will critically describe the
complexity of HER2 equivocal results. Finally, we will introduce the clinical impact of HER2 mutations and we
will define the upcoming category of HER2-low breast cancer with respect to emerging clinical data on the
efficacy of specific anti-HER2 agents in subgroups of breast carcinomas lacking the classical oncogene addition
dictated by HER2 amplification.
1. Introduction
The human epidermal growth factor receptor 2 (HER2) is an orphan
tyrosine kinase receptor belonging to the Human Epidermal Receptor
family. HER2 has no ligand but is a preferred dimerization partner of
the other three receptors of the family [1]. Upon (homo/hetero-)di-
merization among the receptors, downstream tyrosine kinase signaling
cascades are activated thus triggering cell proliferation, migration, in-
vasion, and survival [1].
HER2 is amplified leading to HER2 overexpression in about 15 % of
breast carcinomas [2]. If on one side this mechanism confers a poor
prognosis (due to the effect on cell proliferation, migration, invasion,
and survival, all hallmarks of cancer), on the other side it offers the
unique possibility to use a targeted treatment approach with the
monoclonal antibody trastuzumab, which targets the extracellular do-
main of HER2 thus altering the normal tyrosine kinase signaling
(Fig. 1). Such therapeutic option has radically changed the natural
history of HER2-positive disease since the 90s’. Besides the monoclonal
antibody trastuzumab, which is currently administered together with
chemotherapy in the neoadjuvant, adjuvant and metastatic settings,
other anti-HER2 therapeutic compounds have been developed over the
years (Fig. 1). Pertuzumab, a humanized monoclonal antibody that
binds to HER2 on a different domain than trastuzumab and prevents
homo- and hetero-dimer formations, is routinely added to taxanes and
trastuzumab as the preferred regimen in the first-line setting of ad-
vanced disease [3], and it is also administered in the neoadjuvant set-
ting [4]. Other anti-HER2 compounds (tyrosine kinase inhibitors, such
as lapatinib, or antibody-drug conjugates such as T-DM1) are used
mainly in the metastatic setting or within the context of clinical studies.
It is important to note that although several markers with prognostic
value have been identified in HER2-positive disease over the past years,
at present the best predictive factor for likeliness of response to anti-
https://doi.org/10.1016/j.semcancer.2020.02.016
Received 19 November 2019; Received in revised form 16 February 2020; Accepted 22 February 2020
⁎ Corresponding authors at: Department of Medical Sciences, University of Turin and Unit of Pathology, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale
142, Km 3,95; 10060 Candiolo Torino, Italy.
E-mail addresses: caterina.marchio@unito.it (C. Marchiò), anna.sapino@ircc.it (A. Sapino).
1 Equal contribution.
Seminars in Cancer Biology xxx (xxxx) xxx–xxx
1044-579X/ © 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
Please cite this article as: Caterina Marchiò, et al., Seminars in Cancer Biology, https://doi.org/10.1016/j.semcancer.2020.02.016
HER2 agents is represented by HER2 overexpression/amplification [5].
In diagnostic pathology the HER2 status is routinely assessed by
using a combination of immunohistochemistry (IHC, to evaluate HER2
protein expression levels) and in situ hybridization (ISH, to assess HER2
gene status), the only two techniques with acknowledged clinical va-
lidation [2,5,6]. For this purpose, international recommendations have
been developed by a consensus of experts in the field. These re-
commendations have changed over the years according to new ex-
perimental and clinical data. In this review we will document the
changes that have contributed to a better evaluation of the HER2 status
in clinical practice; in addition we will discuss the different scenarios
encompassing HER2 heterogeneity defined by IHC and ISH as well as by
transcriptomic analysis, the complexity of HER2 equivocal results,
HER2mutations and the upcoming category of HER2-low breast cancer.
2. HER2 evaluation in breast cancer by ASCO/CAP guidelines
In diagnostic practice every newly diagnosed breast carcinoma as
well as any relapses or metastatic deposits are assessed for the HER2
status, which is assigned based on recommendations by an international
group of experts in the field. The American Society of Clinical
Oncology/College of American Pathologists (ASCO/CAP) have drafted
the recommendations for HER2 testing since 2007 [7] by taking also
care to discuss the optimal pre-analytical and analytical requirements
for the performance and interpretation of HER2 testing using IHC and
fluorescence ISH (FISH). The pre-analytical phase has a huge impact on
the correct performance of both IHC and ISH and proper control of cold
ischemia time is paramount in ensuring the preservation of antigens,
DNA and RNA in formalin-fixed, paraffin-embedded (FFPE) tissues
[2,8–10].
The initial clinical trials for trastuzumab used an IHC score 3+ or a
score 2+ with a positive FISH test (defined by HER2/CEP17 ratio ≥2
in> 50 % neoplastic cells) as eligibility criteria. In these trials, an IHC
score 3+ was defined as intense/strong complete circumferential
membrane staining in>10 % cells of neoplastic cells and 2+ was
defined as weak to moderate complete circumferential membrane
staining in> 10 % cells of neoplastic cells [11]. In the 2007 ASCO/CAP
guidelines the threshold for positivity was elevated to>30 % of neo-
plastic cells in IHC and to HER2/CEP17 ratio ≥2.2 by FISH in order to
lower the number of false positive results, decreasing the administra-
tion of ineffective anti-HER2 therapy [7].
In 2009 the ASCO/CAP published a supplement to the 2007
Fig. 1. HER2 downstream pathway activation, anti-HER2 targeted agents. HER2 is a ligand-orphan transmembrane tyrosine kinase receptor belonging to the Human
Epidermal Receptor (HER) family. HER2 homo- or hetero-dimerization with one of the other three receptors (HER1 or EGFR, HER3 and HER4), triggers the activation
of different signaling pathways that are associated with cell proliferation, invasion and survival of cancer cells [1,106]. Therapeutic approaches, based on the
modulation of HER2 activation, include different targets of the protein. Monoclonal antibodies bind the extracellular domain of HER2, with a selective antigen
preference for trastuzumab or pertuzumab, leading to a reduction of the signaling cascade [107]. Antibody-drug conjugates are designed to release the drug after
internalization by the tumor cell, with the decrease of systemic side effects. The small molecules tyrosine kinase inhibitors (TKIs), such as lapatinib and neratinib,
inhibit the catalytic activity of the HER2 receptor in a reversible or irreversible way, respectively, through the specificity for the ATP binding site of the kinase
domain [108]. ADC: Antibody-Drug Conjugate. This image has been created with BioRender.
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guidelines regarding HER2 heterogeneity in FISH assays. It defined
HER2 genetic heterogeneity as the presence of ≥5% to<50 % of in-
filtrating tumor cells with a ratio ≥2.2 when using dual probes or ≥6
HER2 signals/cell using single probes [12]. They recommended two to
four representative areas of the invasive tumor to be selected and as-
sessed after scanning the entire slide to look for heterogeneity; clusters
(> 20 cells) with HER2 amplification by FISH should be separately
assessed and reported in terms of HER2/CEP17 ratio and/or HER2
signals/cell [12].
The 2013 ASCO/CAP guidelines reverted the positivity threshold to
the original> 10 % cells of neoplastic cells in IHC and HER2/CEP17
ratio ≥2 in FISH in order to avoid false negative results [13]. These
recommendations brought the attention to false negative results, which
could deny a potentially life-saving treatment (anti-HER2 therapy) to
breast cancer patients [13]. This position was taken based on the re-
latively low frequency of side effects this treatment may lead to [13]. In
particular, these guidelines introduced the concept of ISH algorithm,
which represents a two-step approach when scoring ISH results taking
into account first the HER2/CEP17 ratio, followed by the analysis of
HER2 mean copy numbers when the HER2/CEP17 ratio is< 2. This
algorithm helped avoid misclassification of HER2 amplification in those
cases harboring abnormal copy numbers of the centromeric region of
chromosome 17 (CEP17). Indeed, we [14] and others [15–17] have
demonstrated that breast carcinomas with such FISH patterns more
frequently harbor true HER2 amplification coupled with gain/amplifi-
cation of the centromeric region of chromosome 17, rather than chro-
mosome 17 (Chr17) polysomy.
Finally, the 2013 ASCO/CAP recommendations further addressed
the issue of HER2 heterogeneity by adopting the same threshold
of> 10 % used in IHC assessment, thus defining HER2 heterogeneity as
the presence of a separate population of cells with a different HER2
copy number and/or HER2/CEP17 ratio accounting for at least 10 % of
the overall tumor cell population [13]. The guidelines recommended
that in these cases a separate counting should be done in at least 20 of
these cells [13].
In 2018 the ASCO/CAP panelists provided an update of these
guidelines, which focuses on five specific clinical questions (Table 1)
[6]. In this respect, the 2018 ASCO/CAP guidelines should be best
considered as an integration of the 2013 edition, rather than a new
version of recommendations. Neither cut-offs or definitions were
amended, rather literature data were reviewed to assess the level of
evidence to suggest a positive or negative result in borderline cases.
As first question to be answered the panelist focus on the correct
definition of score 2+ breast carcinomas that would require a reflex
ISH testing: a weak to moderate complete membrane staining in more
than 10 % of the tumor cell population is required to classify breast
carcinomas as score 2 + . Nevertheless, it is acknowledged that unusual
patterns of HER2 expression can be encountered, featuring for instance
strong but incomplete membrane staining (typical of micropapillary
carcinomas) or strong and complete staining but only in a subpopula-
tion of cells that account for less than 10 % of the entire tumor popu-
lation. In all of these scenarios ISH has to be performed. In the latter
scenario, which is suggestive of high intratumoral heterogeneity, rea-
sonable common practice would include to test additional tumor blocks
to assess the real degree of HER2 overexpression/amplification. These
highly heterogeneous carcinomas are those that would likely benefit
most from retesting at recurrence and/or metastatic progression since
HER2-amplified clones may become dominant and therefore leading to
the addition of anti-HER2 therapy [18].
A second clinical question relates to the mandatory recommenda-
tion that was given in 2013 regarding the repetition of the HER2 testing
on surgical specimens whenever core needle biopsy specimens harbor
negative HER2 results at the initial assessment. The 2018 update tem-
pers this statement by suggesting that HER2 test may be repeated
whenever encountering one of the following instances: i) amount of
invasive tumor in the core biopsy specimen is small; ii) resection
specimen contains high-grade carcinoma that is morphologically dis-
tinct from that in the core; iii) core biopsy result is equivocal for HER2
after testing by both ISH and IHC; iv) there is doubt about the handling
of the core biopsy specimen (long ischemic time, short time in fixative,
different fixative) or the test is suspected by the pathologist to be ne-
gative on the basis of testing error [6].
The remaining three clinical questions are related to ISH results, for
which the recommendations refer to the 5-Group classification pro-
posed by Press and co-workers in 2016 [19]. Group 1 (HER2/CEP17
ratio ≥2, HER2 copy number> 4) and Group 5 (HER2/CEP17
ratio< 2, HER2 copy number< 4) represent the two extremes of the
spectrum of HER2 evaluation (presence and lack of HER2 amplification,
respectively) and the authors indicate that would comprise 95 % of all
dual-probe ISH test results. The remaining 5% would be categorized as
Groups 2–4 [6], featuring challenging scenarios of non-univocal inter-
pretation that have been a matter of debate over the years and for
which the 2018 ASCO/CAP update suggests to perform an additional
work-up based on a combined reinterpretation of ISH and IHC assays to
reach the most accurate HER2 status attribution (positive versus nega-
tive) (Table 1).
In particular, Group 2 identifies tumors in which ISH test results
show HER2/CEP17 ratio ≥2 but mean HER2 copy numbers< 4, a
pattern that often reflects the presence of chromosome 17 monosomy.
In the retrospective analysis of the initial clinical trials for trastuzumab,
although the small sample size for this group made it impossible to
statistically rule out a possible benefit from therapy, most patients did
not seem to have improved outcomes with anti-HER2 treatment [6].
Hence, if the ISH pattern is confirmed during the additional work-up it
is recommended to consider these cases as negative, unless tumor cells
display a score 3+ by IHC [6].
In Group 3 we include cases harboring mean HER2 copy number≥6
and a HER2/CEP17 ratio< 2 due to increased CEP17 copy numbers,
which were labeled as positive thanks to the adoption of the ASCO/CAP
2013 algorithm. These cases are very uncommon (0.4–3 %) and were
not included in the initial trastuzumab clinical trials, therefore there is
limited clinical evidence regarding the benefit from trastuzumab-con-
taining chemotherapy. Nevertheless, based on the demonstration by
several independent groups of occurrence of true HER2 amplification in
these cases [14–17], in particular when HER2 copy numbers are high,
the 2018 update supports the definition of HER2-positivity for these
tumors, unless there is lack of HER2 overexpression (i.e. the specimen
shows a score 1+ or 0 by IHC) [6].
Finally, Group 4 breast carcinomas show equivocal HER2 gene
status (HER2/CEP17 ratio< 2.0 with mean HER2 copy numbers ≥4
and< 6) and would be defined HER2 double-equivocal if showing also
a score 2+ of HER2 expression by IHC. The number of such cases
within a laboratory varies based on the patient population referred for
ISH testing, but it seems to account for approximately 5% of cases
(range: 1 %–16 %) [6]. Breast carcinomas harboring this ISH pattern
were labeled as “equivocal” according to the 2013 recommendation
and the use of anti-HER2 agents was left to the clinician’s choice [13].
There is no doubt that Group 4 cases have posed a challenge to on-
cologists and patients due to a perceived ambivalence about whether to
recommend HER2-targeted therapy. It should also be noted that the
absence of an unequivocally positive or negative test result has led to
multiple testing of the same tissue sample as well as to the use of al-
ternative Chr17 probe testing in the attempt to resolve the HER2 status.
It is important to stress the concept that Chr17 in breast cancer is highly
recurrently altered [14,20,21], therefore the use of alternative Chr17
probes mapping to regions different from the CEP17 may be misleading
rather than of support in these scenario: as an example, by using probes
mapping to the short Chr17 arm, which happens to harbor large
chromosomal losses, the HER2/Chr17-probe ratio may increase and
even lead to a positive result based on mere artefactual calculation.
Furthermore, these alternative Chr17 probes are not analytically or
clinically validated, i.e. they have not been used in clinical trials
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showing efficacy of anti-HER2 therapy [6]. The Expert Panel of the
2018 ASCO/CAP update also strongly recommends against this as a
routine testing strategy and suggest to rely on a re-evaluation of the IHC
score if not performed and to a recount by a second observer of the ISH
experiment [6]. If the double-equivocal result is confirmed after addi-
tional work-up, the carcinoma is preferentially labeled as negative,
since there is uncertainty as whether patients may benefit from HER2-
targeted therapy in the absence of protein overexpression (IHC score
3+) [6]. It should be noted that this is a recommendation conceived in
spite of a gap of knowledge on the potential beneficial effect of a HER2-
targeted treatment in patients with an average of≥4.0 and<6.0 HER2
signals per cell and a HER2/CEP17 ratio of< 2.0. The NSABP B-47 trial
has recently demonstrated that HER2-negative carcinomas (score 1+/
2+ in IHC and ISH-negative) do not benefit from the addition of tras-
tuzumab [22]. Regrettably, HER2 equivocal carcinomas were not in-
cluded in this study and data about treatment response for these
carcinomas are therefore missing.
Not surprisingly, studies available so far on the impact of the 2018
guidelines indicate that application of the new guidelines leads to an
increase in the negativity rate on HER2 testing. This observation stems
from the reclassification of Group 2 and Group 4 cases that are now
recommended to be scored as negative [23,24].
3. Intratumor and intertumor heterogeneity of HER2-positive
breast carcinomas
Intratumor genetic heterogeneity has been well documented in
various types of human cancer, including breast cancer [25]. It is well
known to pathologists routinely assessing HER2 in diagnostic practice
that HER2 overexpression and amplification can present a hetero-
geneous pattern (Fig. 2). Three distinct types of distribution of cells
with heterogeneous HER2 status have been described [26]: “clustered”
Table 1
Summary of HER2 evaluation by ISH following the 2018 ASCO/CAP guidelines.
Assay Method Result Additional work-up Final HER2 assignment
Dual-probe ISH ISH algorithm Group 1
HER2/CEP17 ratio ≥2.0 and average HER2
copy number ≥4.0 signals/cell
/ AMP/Positive
Group 2
HER2/CEP17 ratio ≥2.0 and average HER2
copy number <4.0 signals/cell
Concurrent IHC score 0/1+ NOT AMP/Negative with Comment
Concurrent IHC score 2+, recount ISH:
preliminary result confirmed
NOT AMP/Negative with Comment
Concurrent IHC score 2+, recount ISH:
other ISH result
Result should be adjudicated per
internal procedures
Concurrent IHC score 3+ AMP/Positive
Group 3
HER2/CEP17 ratio <2.0 and average HER2
copy number ≥6.0 signals/cell
Concurrent IHC score 0/1+ NOT AMP/Negative with Comment
Concurrent IHC score 2+, recount ISH:
preliminary result confirmed
AMP/Positive
Concurrent IHC score 2+, recount ISH:
other ISH result
Result should be adjudicated per
internal procedures
Concurrent IHC score 3+ AMP/Positive
Group 4
HER2/CEP17 ratio <2.0 and average HER2
copy number ≥4.0 and <6.0 signals/cell
Concurrent IHC score 0/1+ NOT AMP/Negative with Comment
Concurrent IHC score 2+ (HER2
double-equivocal), recount ISH:
preliminary result confirmed
NOT AMP/Negative with Comment
Concurrent IHC score 2+ (HER2
double-equivocal), recount ISH: other ISH
result
Result should be adjudicated per
internal procedures
Concurrent IHC score 3+ AMP/Positive
Group 5
HER2/CEP17 ratio <2.0 and average HER2
copy number <4.0 signals/cell
/ NOT AMP/Negative
Single-probe ISH HER2 copy
number
Average HER2 copy number <4.0 signals/cell / NOT AMP/Negative
Average HER2 copy number ≥4.0 and <6.0
signals/cell
Concurrent IHC score 0/1+ and/or
concurrent dual-probe ISH Group 5
NOT AMP/Negative
Concurrent IHC score 2+ Perform dual-probe ISH for final result
Concurrent IHC score 3+ and/or
concurrent dual-probe ISH Group 1
AMP/Positive
Average HER2 copy number ≥6.0 signals/cell / AMP/Positive
Legend: AMP: amplified; IHC: immunohistochemistry; ISH: in situ hybridization. Scenarios in which the final result is adjudicated as positive are highlighted in Bold
and Italic.
C. Marchiò, et al. Seminars in Cancer Biology xxx (xxxx) xxx–xxx
4
type, featuring the presence of two topographically distinct tumor
clones of tumor cells, one harboring HER2 amplification and the other
with normal HER2 status; “mosaic” type, displaying either diffuse in-
termingling of cells with different HER2 statuses; “scattered type”, with
isolated HER2-amplified cells in a HER2-negative tumor cell popula-
tion.
Several studies have demonstrated the presence of HER2 genetic
heterogeneity at variable frequencies (1–34 %) in breast cancer
[27–36], being significantly more common in cases with HER2 equi-
vocal status by ISH and/or IHC [27,30,33,34,37]. For instance, Allison
et al. [27] and Chang et al. [29] found that> 90 % of FISH HER2
equivocal cases presented HER2 heterogeneity; Bukley et al. observed
that the highest levels of heterogeneity were detected in HER2 border
line cases as well as in HER2-negative cases with highest HER2/CEP17
ratios [18]. Some have suggested that HER2 heterogeneity is an im-
portant cause of equivocal HER2 results in breast cancer by FISH and
IHC [18,36,37]. In this respect, our group has demonstrated that
whenever assessing HER2 status in breast carcinomas with a diffuse
intermingling of HER2-amplified and non-amplified cells leads to HER2
equivocal counts [38]. These cases typically feature low levels of HER2
amplification [38], as observed also by others [28,33,36,39].
Some studies have also associated increased frequency of chromo-
some 17 polysomy with HER2 heterogeneity [37,39,40]. As already
mentioned, chromosome 17 polysomy is a rare event in breast cancer,
which features more frequently gain or amplification of the chromo-
some 17 centromere (CEP17) [14–17]. Hence, the term CEP17 ab-
normal copy number should be used in this context (especially if as-
sessed by FISH in interphase nuclei). Nevertheless, this phenomenon of
increased CEP17 copy numbers independently observed in HER2 het-
erogeneous carcinomas may support the theory that HER2 hetero-
geneity is caused, at least in part, by chromosomal instability [40].
In terms of impact on patient outcome, Shafi et al. [37] found that
HER2 FISH non-amplified tumors with genetic heterogeneity were as-
sociated with larger size, higher histologic grade and frequency of
lymph node metastasis, which are important negative prognostic fac-
tors in breast cancer. Several studies indicate that the presence of HER2
heterogeneity is associated with worse patient outcomes, in terms of
shorter disease free survival and overall survival [32,33,40]. When
analyzing the response to treatment, patients with HER2 heterogeneity
seem to be less responsive to anti-HER2 targeted therapy [30,41–43], as
also demonstrated by lower achievement of pathologic complete re-
sponse (pCR) following neoadjuvant treatment with trastuzumab-con-
taining chemotherapy [35,38]. These results have been recently con-
firmed in an elegant study presented at ASCO 2019 by Metzeger Filho
and co-workers, who designed a Phase II study in which evaluation of
response of stage II and stage III centrally confirmed HER2-positive
breast carcinomas to neoadjuvant T-DM1 and pertuzumab was per-
formed. HER2 heterogeneity in diagnostic core needle biopsy samples
was defined either as i) HER2 positivity by FISH in>5% and<50 % of
tumor cells [12]; ii) an area of the tumor that was tested negative. HER2
heterogeneity was found in 10 % of cases (n = 16/157). pCR was not
achieved in any of the heterogeneous cases compared to 55 % of HER2-
positive carcinomas without evidence of HER2 heterogeneity. The as-
sociation between HER2 heterogeneity and pCR remained significant
when adjusted by estrogen receptor (ER) status. These data suggest that
HER2 heterogeneous breast carcinomas may represent a distinct subset
of HER2-positive tumors for which different therapeutic approaches
may be considered [44].
A genomic analysis based on gene copy number profiling and
massively parallel sequencing of HER2-negative and HER2-positive
components of 12 HER2 heterogeneous breast cancers identified po-
tential driver genetic alterations restricted to the HER2-negative cells in
each case. In in vitro models BRF2 and DSN1 overexpression/amplifi-
cation and the HER2 I767M mutation were shown to be alterations that
compensate for the lack of HER2 amplification in the HER2-negative
components of HER2 heterogeneous breast carcinomas [45].
Another important aspect to consider is intertumor heterogeneity of
HER2-positive disease. First, up to 45 % of cases may also express
variable levels of hormone receptors; second, there is a variable com-
position of molecular subtypes; finally, different genetic alterations can
be observed across tumors.
Although hormone receptor status seems not to determine the
Fig. 2. Intratumor heterogeneity of HER2 expression. Representative micrographs of heterogeneous patterns of HER2 protein expression assessed by im-
munohistochemistry in breast carcinomas. (A) A sample showing two discrete tumor clones, one showing a HER2 expression scored a 3+ and one lacking HER2
overexpression with some interspersed isolated HER2-positive cells (inset). (B) A breast carcinoma with a variable degree of HER2 expression with some areas
featuring a score 2+ (dashed lines) and other areas score 1+ (dashed lines with dots). (C) A sample with aggregated HER2 score 2+ cells (arrows) surrounded by
HER2 score 1+ cells. (D) Scattered HER2 score 2+ cells (arrows) within a HER2 score 1+ tumor cell population. Micrographs were taken from samples routinely
analyzed for HER2 assessment and for which an informed consent for research studies was also signed.
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overall genetic profile of HER2-amplified breast carcinomas, specific
genetic aberrations may be characteristic of subgroups of HER2-positive
breast cancers [46–48]. Hormone receptor status is also impacting, at
least in part, on the distribution of intrinsic molecular subtypes of
clinically defined (i.e. by IHC/FISH) HER2-positive carcinomas. The
large majority is represented by HER2-enriched carcinomas, however a
non-negligible number of luminal carcinomas (luminal B being more
prevalent than luminal A) and basal-like carcinomas have been con-
sistently reported [46,49,50].
Of note, HER2-positive breast cancers defined as “HER2-enriched”
by transcriptomic analysis have high response rates to anti-HER2
therapy, thus identifying a category of super-responders to anti-HER2
compounds [50,51]. Prat and co-workers [52] have recently analyzed
HER2 mRNA levels and the HER2-enriched intrinsic subtype by PAM50
in HER2-positive disease treated with dual HER2-blockade without
chemotherapy in five neoadjuvant clinical trials (SOLTI- PAMELA,
TBCRC023, TBCRC006, PER-ELISA, EGF104090). The PAM50-defined
HER2-enriched intrinsic subtype was significantly associated with high
HER2 mRNA levels and higher pCR rate compared to the rest [52].
These data suggest that this biomarker could help de-escalate che-
motherapy in approximately 40 % of patients with HER2-positive
breast cancer [52].
As a matter of fact, there is a wide interpatient variability across the
different intrinsic subtypes in HER2-amplified patients. In a set of 66
HER2-amplified breast carcinomas analyzed by whole genome se-
quencing, TP53 mutations were detected only in tumors characterized
by a HER2-enriched PAM50-derived subtype, without any alterations in
the PI3KCA gene. Conversely, breast carcinomas classified as luminal
showed a high frequency of PIK3CA mutations and no TP53 alterations
[46]. Interestingly, in a cohort of HER2-positive carcinomas subjected
to neoadjuvant anthracycline-taxane-based chemotherapy plus anti-
HER2 treatment PIK3CA mutated carcinomas (21.4 % of the overall
cohort) were less likely to achieve a pCR compared to PIK3CA wild-type
tumors. The difference in terms of pCR rate between PIK3CA wild type
and PIK3CA mutated tumors was more pronounced for hormone re-
ceptor positive carcinomas [53].
In a series of HER2-positive/ER-positive breast carcinomas showing
a better prognosis and reduced benefit from trastuzumab compared
with the HER2-positive/ER-negative carcinomas, Zhao and co-workers
reported a reduced rate of TP53 mutations and a lesser degree of HER2
expression at both mRNA and protein levels [54].
4. HER2 status by RNA-based methods
A high correlation between HER2 gene status and HER2 mRNA le-
vels is well known, as documented by several studies [55–57]. This has
allowed to consider RNA evaluation as a possible option for HER2 as-
sessment. The aim is to understand whether RNA-based testing could be
able to complement IHC and DNA FISH analysis, allowing a full re-
solution of the HER2 status. Several techniques have been applied for
HER2 mRNA analyses, including quantitative procedures and in situ
detection methods, however they are not widely used in clinical prac-
tice even though the determination of biomarkers by RNA evaluation is
becoming more feasible.
The possibility to perform HER2 mRNA testing by real-time quan-
titative PCR (qPCR) has been extensively evaluated [57–59]. The op-
portunity to use qPCR to assess in a single reaction HER2 DNA ampli-
fication and mRNA expression in microdissected breast carcinomas has
been investigated and, despite the unavoidable degradation of nucleic
acids that occurs in FFPE tissue samples, the detection of HER2 mRNA
was successful in 94 % of samples [57].
Given that qPCR is quantitative and objective, while IHC is semi-
quantitative and observer-dependent, qPCR approaches have been
proposed as alternative to IHC to reduce the variability of im-
munohistochemistry. Denkert and co-workers [60] found that HER2
mRNA expression was higher and detectable with gradually increasing
expression levels in ER-positive tumors, while distinct groups of HER2-
positive and HER2-negative tumors were identified in ER-negative cases
[60]. The continuum of HER2 mRNA expression in ER-positive cases
has called into question the selections of cut-off levels for HER2 as-
sessment, highlighting the need of further evaluation of HER2 mRNA
expression in additional cohorts. Dabbs and co-workers [61] evaluated
the concordance between laboratory HER2 results by FDA-approved
IHC and FISH assays and HER2 mRNA assessment by qPCR separately
reported by the Oncotype DX test. Their results demonstrated that the
false-negative rate for Oncotype DX qPCR for HER2 was greater than 50
% [61]. The authors spoke a word of caution especially for those
equivocal or negative qPCR results in unequivocally HER2-positive
patients by using FDA-approved procedures. This is why mRNA-based
techniques are not recognized as alternative methods to assess HER2
status in diagnostic practice, as stated also by the ASCO/CAP guide-
lines.
Many causes have been suggested to explain discordant results.
Heterogeneity of HER2 expression/amplification is likely key in this
respect, but cases with low HER2 level amplification may contribute, at
least in part, to these discordances: as a matter of fact thresholds in ISH
analysis are used and unselected cases classified as HER2-positive by
ISH may have a wide range of HER2 amplification.
Droplet digital PCR (ddPCR) is another method for mRNA evalua-
tion and is based on partitioning the PCR reaction mixture into thou-
sands of droplets so that each droplet contains either 1 or 0 molecules of
target RNA. It is capable of quantifying mRNA expression with high
precision. From the advent of this technique, several studied have been
proposed with the aim to assess HER2 expression in breast carcinomas.
Meehan and colleagues demonstrated that ddPCR can be applied in
FFPE tissues to measure HER2 mRNA [62]. When applying a cut-off of
490 mRNA HER2 copies/μl a perfect (100 %) agreement was found in
discriminating HER2-positive from HER2-negative cases. They included
in their analysis also 6 HER2 equivocal cases based on the 2013 ASCO/
CAP Guideline Recommendations and these cases were consistently
classified as negative by ddPCR [62]. In another study ddPCR was ap-
plied for HER2 mRNA determination in both breast and gastric cancer
samples, with the final ambition to find a possible role for ddPCR in
handling the two clinical challenges of equivocal cases and intratumor
heterogeneity [63]. The ddPCR assay defined the IHC and FISH double-
equivocal case as HER2-negative patients [63]. The authors acknowl-
edged that the weakness of ddPCR is that high intratumor heterogeneity
of clinical sample is likely to generate false negative results [63]. The
loss of spatial information represents indeed one of the major dis-
advantages of in vitro mRNA-based assays [64].
To avoid the drawbacks related to standard molecular procedures,
in situ mRNA detection methods have been proposed (Fig. 3). Wang
et al. developed a novel in situ RNA analysis platform for FFPE tissues,
the so called “RNAscope” [65], which has been reported superior to
qPCR in cases with intratumor heterogeneity or equivocal/double-
equivocal results by IHC and FISH [65]. The RNAscope HER2 assay was
performed in seven cases with heterogeneous IHC staining patterns but
unequivocal FISH results (five amplified and two unamplified) and
RNAscope classified them with 100 % accuracy when compared with
FISH. In contrast, qPCR showed only 42.8 % agreement with FISH. In
equivocal cases, RNAscope was able to classify those cases that were
equivocal by FISH into HER2-positives and negatives, which agreed
with IHC when the IHC results were unequivocal. The FISH/IHC
double-equivocal cases were not different at the mRNA level from those
that were FISH equivocal only and RNAscope classified 7 on 26 cases
(27 %) as positive [66].
Our group has participated to the validation of a single-molecule
RNA FISH protocol for the detection of RNA in FFPE tissue sections
(FFPE-smFISH), which was applied to quantify the expression and the
intratumor spatial heterogeneity of HER2 in a series of breast carci-
nomas with different HER2 status [67]. In our series we were able to
observe that one IHC 2+/DNA FISH-negative case had HER2
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expression levels similar to tumors in the IHC 2+/DNA FISH-positive
and IHC 3+ groups. Conversely, several tumors from patients in the
IHC 2+/DNA FISH-positive group, who received targeted therapy in
agreement with 2013 ASCO/CAP guidelines, showed HER2 expression
levels close to those in the IHC 2+/DNA FISH-negative group [67].
These data raise the question as whether this assessment may be of
support in identifying patients more likely or less likely to respond to
treatment, especially in those rare cases currently categorized as HER2-
negative, in which HER2 mRNA levels are similar to those of score 2+/
HER2-amplified and score 3+ cases.
By performing quantitative measurements at multiple, distinct
spatial areas in the tumor, we were able to measure various aspects of
intratumor transcriptional heterogeneity: we observed that tumors be-
longing to the same molecular subtype had different transcriptional
intratumor heterogeneity profiles, suggesting that not only the type and
average expression level, but also the spatial distribution of cells ex-
pressing a given biomarker might influence how a tumor evolves and
responds to therapy [67].
Schilz and co-workers tried to link transcript, protein, and signaling
networks in tissues with spatial resolution: they proposed an applica-
tion of imaging mass cytometry to enable multiplexed detection of
mRNA and proteins in tissues [68]. A good correlation was found for
HER2 mRNA and HER2 protein in a series of 70 breast carcinomas with
different HER2 status. A significant upregulation of the HER2 mRNA
was identified in 21 of the 26 samples with HER2 amplification and in
16 of these cases HER2 mRNA levels were more than 10-fold higher
than levels in control tissues. In 19 of the 26 samples with HER2 am-
plification a significant expression of HER2 protein was detected com-
pared with control tissues. Three of these 19 HER2-amplified samples
showed significant overexpression of the HER2 protein but their levels
of HER2 mRNA were lower than in most other amplified samples. Due
to the complexity of the technique and the use of FFPE samples some of
these differences may be related to RNA degradation, nevertheless it
would be of interest to ascertain whether some of these mRNA-to-
protein level ratio differences across patient samples could be due to
patient-specific deregulation that might be reflected in clinical features
[68].
5. HER2-low breast carcinomas: a new entity in the field
Pathologists have traditionally aimed at separating HER2-positive
from HER2-negative breast carcinomas. This dichotomous diagnostic
work-up, strengthened by the 2018 ASCO/CAP update, has been dic-
tated by solid clinical data demonstrating that only tumors driven by
HER2 oncogene addition benefit from the addition of trastuzumab to
chemotherapy [22]. Hence, medical oncologists have applied a binary
treatment decision making when considering HER2, based on the as-
sumption that only HER2-positive patients defined by HER2 over-
expression and amplification should be offered anti-HER2 agents.
In recent years new therapeutic compounds have been developed, in
particular antibody drug conjugates (ADCs) that are designed to target
and deliver chemotherapy inside cancer cells thus reducing systemic
exposure to the cytotoxic agent (Fig. 4). The first in class ADC targeting
HER2 is composed of trastuzumab and the cytotoxic agent emtansine
(T-DM1) at a drug antibody ratio of 3.5. T-DM1 has showed superior
efficacy and a favorable risk-benefit profile as compared with capeci-
tabine plus lapatinib or treatment of the physician’s choice in two phase
3 trials involving patients with HER2-positive advanced breast cancer
who had previously received HER2-targeted therapy including trastu-
zumab and chemotherapy [69–71]. T-DM1 is currently approved for
use in patients with HER2-positive metastatic breast cancer who pre-
viously received treatment with trastuzumab and a taxane [72]. More
Fig. 3. Immunohistochemistry, DNA-FISH and RNA-FISH for HER2. Assessment of HER2 status in two human breast cancer cell lines. BT-474 cells are HER2-positive,
showing a score 3+ protein expression (A), HER2 amplification detected by DNA FISH (B; red: HER2, green: CEP17) and high levels of HER2 mRNA (C) assessed by
HuluFISH probes (PixelBiotech GmbH, provided from MetaSystems s.r.l.). MCF7 cells are HER2 negative at protein level (D) and lack HER2 amplification (E; red:
HER2, green: CEP17): when assessed by mRNA FISH only rare red signals can be appreciated (F).
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recently, results from the Katherine study has shown a significant ad-
vantage for T-DM1 in patients with a residual disease following
neoadjuvant trastuzumab-containing chemotherapy [73].
Other ADCs have been introduced, such as trastuzumab duo-
carmazine (SYD-985) and trastuzumab deruxtecan (DS-8201), which
have demonstrated encouraging response rates not only in HER2-posi-
tive but also in the so called “HER2-low” breast cancer patients
[74–77].
Trastuzumab duocarmazine (SYD-985) comprises the monoclonal
antibody trastuzumab covalently bound to a linker drug containing
duocarmycin, with a drug:antibody ratio of 2.8:1. The linker drug
contains a cleavable linker and the prodrug seco-DUBA: following
HER2-binding and internalization, the linker is cleaved in the lysosome
by proteases that release the active toxin (DUBA), which alkylates DNA
thus resulting in DNA damage in both dividing and non-dividing cells
and ultimately cell death. Treatment with trastuzumab duocarmazine
led to partial response in 28 % and 40 % of HER2-low ER-positive and
ER-negative breast cancer patients, respectively [74].
Trastuzumab deruxtecan (DS-8201) is comprised of trastuzumab
attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-
based linker. It shows a drug-to-antibody ratio higher than that of T-
DM1 (7.8:1) and a potent bystander effect. The results of the phase 2
study in HER2-positive heavily pretreated metastatic breast cancer
patients (median of 6 previous lines of therapy with T-DM1, trastu-
zumab, pertuzumab, and other anti-HER2 therapies) showed a response
rate of 60.9 %, with 6% of patients achieving a complete response, and
54.9 % a partial response [78]. Interestingly, the phase 1 study of DS-
8201 reported also data on pretreated HER2-low metastatic breast
cancer patients demonstrating an overall response rate by independent
central review of 37 % with a median duration of response of 10.4
months in 54 extensively pre-treated patients [75]. At present, a phase
3 study evaluating the safety and efficacy of DS-8201 in patients with
HER2-low, unresectable and/or metastatic breast carcinomas pre-
viously treated with standard chemotherapy is ongoing (DESTINY-
Breast04; ClinicalTrials.gov Identifier: NCT03734029).
Taken together these data may call into question the need of a
paradigm shift in the definition of HER2 status in breast cancer, which
in the next future could be based on a 3-tier system featuring i) HER2-
positive, ii) HER2-negative, and iii) HER2-low breast carcinomas
(Fig. 5). The latter category would represent an example of carcinomas
potentially benefitting from a targeted therapy because of the presence
of the target (which allows the drug to attach and exert the action) even
in the absence of the addition of the tumor cells to the HER2 oncogene
(Fig. 5).
Two factors may be relevant in the mechanism of action of these
drugs and may help define possible responsive carcinomas: on one side,
the minimum quantity of HER2 receptors to be present on tumor cell to
offer an anchor to the drug to work; on the other side, the degree of
bystander effect the drugs can exert to spread their activity also to
neighboring cells that could be even HER2-negative (Fig. 4).
In a study using HER2-targeted liposomal doxorubicin as a model-
targeted nanoparticle to quantitatively investigate the effect of HER2
expression levels on delivery of doxorubicin to the nucleus, a quanti-
tatively greater nuclear doxorubicin delivery was observed with in-
creasing HER2 expression. A threshold effect was seen at approximately
200,000 HER2 receptors/cell [79], which may also constitutes the
threshold of HER2 expression that separates toxic from therapeutic
actions of HER2-targeting drug conjugates.
Studies have shown that a range of 100,0000–500,000 HER2 re-
ceptor molecules are present on the membrane of score 1+ and 2+
breast carcinoma cells, compared to more than two millions on score
3+ cells [80]. Although there are no formal definitions of HER2-low
breast carcinomas, at present it seems reasonable to identify as HER2-
low breast carcinomas those displaying a score 1+ or a score 2+ of
HER2 expression and lacking HER2 amplification (Fig. 5). Based on this
definition, up to 55 % of all breast carcinomas would be categorized as
HER2-low. Of note, for this subtype there are no targeted treatments
approved, and this stresses once more the impact agents effective in
HER2-low breast cancer may have. At present, ER-positive breast
cancer patients are treated with a combination of endocrine therapy
+/- chemotherapy whereas ER-negative (at present defined as “triple
negative”) patients are treated with chemotherapy.
The category of HER2-low breast cancer clearly constitutes a spec-
trum of carcinomas with different degrees of HER2 expression, the
highest end of which is represented by score 2+ carcinomas.
Independent groups have demonstrated that these carcinomas have a
poorer prognosis compared to HER2-negative breast carcinomas
[81–83] and this holds true when cases are categorized in the different
immunophenotypical subtypes (luminal-like and triple negative) [81].
Although HER2-low carcinomas can populate both luminal and non-
luminal subtypes, they are typically ER-positive [81,84–86] and pre-
ferentially pertain to the luminal B molecular subgroup by gene ex-
pression analysis [38]. They tend to be of higher histologic grade and to
harbor higher proliferation rates compared to ER-positive/HER2-ne-
gative disease [81,84–86]. One relevant point to discuss in this context
relates to heterogeneity, as these carcinomas are those in which the
highest prevalence of HER2 heterogeneity has been reported, more
frequently featuring a pattern of diffuse intermingling of HER2-positive
Fig. 4. Mechanism of action of antibody drug
conjugates (ADCs). Antibody-drug conjugates
(ADCs) are monoclonal antibodies covalently
bound to cytotoxic agents and are designed to
target and deliver chemotherapy inside cancer
cells thus reducing systemic exposure to the
cytotoxic agent. After ADC binding to cell
surface antigens, the ADC-antigen complex is
internalized and the released payload mediates
the killing of antigen expressing cells. ADCs
have been shown to be active also against
surrounding cells: the payload released into the
extracellular space can be taken up also by
neighboring HER2-negative cells causing their
death even without expressing the specific
target (bystander killing or bystander effect).
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and HER2-negative tumor cells [2]. We have recent data showing a
higher response rate in score 2+ than score 1+ breast cancer patients
[75], however whether or not the degree of response may vary ac-
cording to presence and type of heterogeneity is yet to be elucidated.
Nevertheless, one could speculate that mosaic-type heterogeneity may
not be a relevant issue in this context thanks to the potent bystander
effect that these drugs show (Fig. 4).
Data from ongoing trials may provide more information on the
correlation between response to treatment and HER2 expression pat-
terns as well as with possible other predictors of response. One may
wonder that, on top of the presence of a certain degree of HER2 re-
ceptor expression on the cell membrane, which is key for the ADCs to
exert its action, mRNA levels and degree of HER2 pathway activation
may also impact in this context. This could be studied by assessing the
correlation between HER2 protein and mRNA levels or by studying the
assignment of the HER2-enriched subtype in the whole lesion. As an
example, by studying HER2 double-equivocal carcinomas at the tran-
scriptomic level, although we observed HER2mRNA levels more similar
to those of score 0 and score 1+ carcinomas, a subset of these carci-
nomas could be classified as HER2-enriched [38].
Finally, HER2-low breast carcinomas may be heterogeneous in
terms of tumor infiltrating lymphocytes (TILs) enrichment in the mi-
croenvironment, which could be relevant in terms of antibody depen-
dent cellular cytotoxicity.
6. HER2 mutations
Activation of the HER2 downstream pathway has always been
thought by being exclusively driven by gene amplification, nevertheless
studies based on massively parallel sequencing (next generation se-
quencing, NGS) have brought to the forefront that breast carcinomas
can harbor HER2 activating mutations. HER2 somatic mutation are less
prevalent than HER2 amplification as they occur in about 2.7 % of
breast cancer patients [87] and they more frequently occur in HER2-
negative or HER2-low breast carcinomas [2,88]. Among breast carci-
nomas harboring HER2 alterations, the co-occurrence of gene amplifi-
cation and mutation has been identified in less than 1% of the speci-
mens [89–91]. Targeted sequencing of three independent cohorts of
unselected breast carcinomas reported in the TCGA dataset a HER2
mutation rate comprised between 2.8 % and 4.6 % and surprisingly
revealed also a 0.2%–1.4% prevalence of fusion between the HER2 gene
and different partners [92–95].
The large majority of HER2 mutations described so far affect exons
19–20 coding for the tyrosine kinase domain (Fig. 6), whereas the re-
maining relate to the extracellular domain (exon 8 mainly, Fig. 6)
[88,89]. In a large series of 5605 cases of advanced/metastatic breast
cancer 90 % of HER2 mutations occurred in the kinase domain and the
remaining 10 % in the extracellular domain [89]. The most common
mutations in this study were L755S, V777L and D769H/Y, which are
missense mutations in the kinase domain of the protein [89]. Missense
mutations (S310F and S310Y) were the most common alterations in the
extracellular domain [89], affecting the furin-like cysteine-rich domain
that is crucial for the receptor dimerization [96]. In this study PIK3CA
was the most common (42 %), statistically significant, co-mutated gene
in tumors harboring HER2 mutation. They also found a concomitant
CDH1 mutation in 37 % of tumors with HER2 mutation [89], which is
not surprising given that studies correlating HER2 somatic mutation
with clinicopathological features reported an enrichment in the lobular
histologic type [89,90,97] and some authors have reported an asso-
ciation with the solid variant of high grade invasive lobular carcinomas
[98].
Wang et al. [91] studied a cohort of 1348 breast cancer patients and
demonstrated that patients with HER2 mutations had a significantly
worse relapse free survival compared to those with wild-type tumors
considering the entire cohort and also when analyzing patients with
HER2 non-amplified tumors only.
Fig. 5. A paradigm shift in the definition of HER2 status in breast cancer. The present dichotomous way of scoring HER2 (positive versus negative) may be revisited
soon by introducing a 3-tier system, here exemplified, featuring i) HER2-positive (red arrow, including score 3+ and score 2+ with HER2 amplification), ii) HER2-
negative (score 0) and iii) HER2-low breast carcinomas (score 1+ and score 2+ without HER2 amplification). The category of HER2-low breast cancer constitutes a
spectrum of carcinomas with different degrees of HER2 expression: at present, as depicted in the Figure they are defined as carcinoma showing HER2 expression
classified as score 1+ or score 2+ and lacking HER2 amplification, however they may harbor HER2 gain (former HER2 equivocal category). The relevance of this
classification is based on promising results on efficacy of some anti-HER2 agents also in the subpopulation of patients affected by breast carcinomas not HER2-
addicted yet showing some degree of HER2 expression (HER2-low) [74,75].
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Bose and co-workers [88] used transformed cell lines to test the
oncogenic capability of the most common HER2mutations. Seven of the
13 functionally characterized HER2 mutations (G309A, D769H, D769Y,
V777L, P780 in., V842I, and R896C) were activating mutations, as they
were found to have greater tyrosine kinase activity and/or increased
dimer formation capacity than the wild-type counterpart. The L755S
HER2 mutation did not promote oncogenic transformation in cell cul-
tures but showed resistance to lapatinib. One mutation, del. 755-759
increased phosphorylation of HER2 heterodimerization partners, EGFR
and HER3. When testing the sensitivity to various HER2 targeted-
therapy, the irreversible HER2/EGFR tyrosine kinase inhibitor ner-
atinib was capable of inhibiting the proliferation of cells bearing all
mutations.
The relevance of detection of HER2 mutations in breast cancer pa-
tients resides indeed in the identification of patients who can possibly
be treated with specific tyrosine kinase inhibitors (TKIs), such as ner-
atinib. Hyman and co-workers [99] have reported data from a large
basket trial with neratinib observing the greatest degree of activity in
patients with breast cancer with an objective response rate at week 8 of
32 %. Responses were observed in patients with missense mutations
involving the extracellular and kinase domains, as well as insertions in
the kinase domain [99].
HER2 mutation can also be a mechanism of resistance to anti-HER2
therapeutic compounds (Fig. 6). Xu et al. [100] showed that the gain of
the HER2 L755S mutation is an acquired mechanism of resistance to
HER2 targeted-therapies and that dual HER1/2 irreversible kinase in-
hibitors can overcome the resistance, as observed in in vitro models of
breast cancer cell lines harboring this mutation [100]. Moreover, the
HER2 K753E mutation gave resistance to reversible but not to irrever-
sible HER2 tyrosine kinase inhibitors in three different breast cancer
cell models [101]. Recently, Kong and co-workers demonstrated that
three HER2 mutations (Q429R, Q429H and T798M) established in
MCF7 breast cancer cells strongly reduced the effect of the trastuzumab
compared to wild-type MCF7 cells, through the dysregulation of the
PI3K-AKT pathway [102]. Similarly, mutations in the HER2 trans-
membrane domain occurring in the residue 659 and 660 have been
associated with resistance to trastuzumab in other malignancies, such
as lung adenocarcinomas, retaining the sensitivity to the afatinib [103].
Furthermore, Hanker and co-workers [104] in a series of metastatic
breast cancer patients identified a novel HER2 mutation (T798I)
occurring in the “gatekeeper” residue within the kinase ATP-binding
pocket mutation and inducing resistance to neratinib in vivo. In silico
analysis predicted that isoleucine substitution at position 798 is able to
confer resistance to neratinib by diminishing the size of its binding site.
Cells harboring the HER2 T798I mutation lacked transforming ability.
This suggests that HER2 T798I is not a driver mutation but is most
probably acquired due to therapeutic pressure. The authors also de-
monstrated that in vitro afatinib was able to overcome HER2 T798I-
mediated drug resistance [104]. Finally, an unpredictable role of HER2
mutations during the treatment of non-HER2-enriched breast cancer
has been described by Nayar and co-workers [105], who analyzed a
series of biopsies from metastatic sites of eight patients, who received
fulvestrant or aromatase inhibitors and developed resistance. Each pa-
tient showed a HER2 metastasis-private mutation, not detected in the
primary breast cancer, suggesting a therapeutically evolutionary pres-
sure at the base of the development of the HER2 alteration [105]. In
vitro analysis on breast cancer cells confirmed that mutations on both
tyrosine kinase and transmembrane domain conferred resistance to
both hormonal therapy and aromatase inhibition [105].
7. Conclusions
The assessment of HER2 is key to treatment decision making for
breast cancer patients. At present, this is achieved by a combination of
immunohistochemical and DNA in situ hybridization analyses.
Nevertheless, it has become clear that HER2-positive carcinomas can be
highly heterogeneous and this may hamper the correct identification of
true responders to anti-HER2 agents. Transcriptomic analysis may be
instrumental in the identification of “HER2-enriched” carcinomas that
are highly sensitive to anti-HER2 agents regardless of the addition of
chemotherapy, thus opening the possibility to de-escalate che-
motherapy for a subgroup of HER2-positive breast cancer patients.
In addition, although rare, HER2 mutations are emerging as im-
portant molecular alterations to be identified for instance in metastatic
patients since HER2 mutated tumors may be responsive to specific
tyrosine kinase inhibitors, as showed by recent clinical studies.
Finally, the dichotomous definition of HER2-positive versus HER2-
negative disease is currently experiencing a wave of changes by in-
cluding the identification of the “HER2-low” category, for which new
therapeutic compounds in the form of potent antibody drug conjugates
Fig. 6. Domain distribution, prevalence and
significance of HER2 somatic mutations.
Lollipop plot representing the absolute fre-
quency and the aminoacidic residues involved
in the most common mutations reported for the
HER2 gene. The lollipop plot underlines the
presence of rare hot-spot variants, belonging to
exons 19-20 and encompassing the tyrosine
kinase domain [88,89]. The biological sig-
nificance for each mutation is represented by
different shapes: mutation with oncogenic
boost effect are pictured with triangles,
whereas squares and circles represent variants
of neutral or unknown significance
[88,95,104]. Some of the reported mutations
showed differential behaviors with respect to
anti-HER2 treatments: in particular, green al-
terations describe mutations conferring sensi-
tivity to the tyrosine kinase inhibitor neratinib
and lapatinib [88]. The red, pink and orange
filled shapes summarize the different muta-
tions associated with resistance to lapatinib,
neratinib and trastuzumab, respectively
[88,102,104,105]. Most of the mutations are
with unknown significance (grey). ECD: ex-
tracellular domain, TM transmembrane do-
main, IND: intracellular domain.
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may be effective.
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